Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC
Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.
Grace Dy, MD, medical oncology, Roswell Park Comprehensive Cancer Center, discusses the use of sotorasib (Lumakras) in patients with non–small cell lung cancer (NSCLC) with KRAS G12C mutations.
The phase 1/2 CodeBreak 100 trial (NCT03600883) investigated sotorasib in pretreated patients with KRAS G12C–mutated NSCLC.
At 2 years of follow-up, which included an additional 48 patients from a phase 1 cohort, the updated objective response rate was about 41%, which fell within the expected range based on initial data, Dy says. Additionally, the median progression-free survival was about 6 months, Dy explains.
The updated results also examined patients who achieved responses during the initial findings, Dy explains. The analysis showed that about 51% of initial responders remained in response for 12 months or longer, and the median duration of response in these patients was 12.3 months, Dy concludes.
